Xvivo Perfusion AB (publ) (STO:XVIVO)
Sweden · Delayed Price · Currency is SEK 284.00
+4.00 (1.43%)
Jul 6, 2026, 5:29 PM CET
Xvivo Perfusion AB Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Xvivo Perfusion AB stock has a consensus rating of "Strong Buy" and an average price target of kr 347.40. The average 1-year stock price forecast is 22.32% higher than the current stock price, while the lowest is kr 310.00 (+9.15%) and the highest is kr 385.00 (+35.56%).
Price Target: kr 347.40 (+22.32%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xvivo Perfusion AB stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Financial Forecast
Revenue This Year
987.05M
from 812.17M
Increased by 21.53%
Revenue Next Year
1.27B
from 987.05M
Increased by 28.92%
EPS This Year
3.84
from 0.85
Increased by 350.89%
EPS Next Year
6.75
from 3.84
Increased by 75.90%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is SEK.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 996.0M | ||
| Avg | 987.1M | ||
| Low | 980.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 22.6% | ||
| Avg | 21.5% | ||
| Low | 20.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 5.27 | ||
| Avg | 3.84 | ||
| Low | 2.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 519.2% | ||
| Avg | 350.9% | ||
| Low | 249.0% |